The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Lupus Nephritis: Understanding the Paradigm for Treatment

Lupus Nephritis: Understanding the Paradigm for Treatment

June 16, 2020 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR BEYOND LIVE—Among patients with systemic lupus erythematosus (SLE), lupus nephritis remains one of the leading causes of mortality, and patients with both SLE and end-stage renal disease demonstrate standardized mortality ratios higher than 60 times that of patients with SLE who have normal kidney function.1 Although the ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis, published in 2012, appear to be straightforward in terms of choices for induction and maintenance therapies, the complex biology and heterogeneous phenotypes of lupus nephritis make the story more complicated.2

You Might Also Like
  • Treatment of Lupus Nephritis Continues to See Progress
  • Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances
  • 2015 ACR/ARHP Annual Meeting: Latest Clinical Literature Offers New Strategies in Lupus Nephritis
Explore This Issue
July 2020
Also By This Author
  • More Equal Care: The Power of Diversity, Equity & Inclusion in Rheumatology

At the 2020 ACR State-of-the-Art Clinical Symposium, Joan Merrill, MD, director of clinical projects in the Arthritis & Clinical Immunology Research Program at the Oklahoma Medical Research Foundation, Oklahoma City, discussed updates in the understanding and treatment of lupus nephritis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Merrill began her talk by noting several baseline characteristics of patients with lupus nephritis that may portend a poor prognosis, such as non-European ancestry, young age, elevated serum creatinine or chronicity index, class IV lesions on biopsy, and anti-Ro antibodies. In particular, she stated that it’s important to pay attention to tubulointerstitial involvement on renal biopsy, because it may be a significant indicator of high risk for progression to renal failure.3

Many rheumatologists are aware of such options as cyclophosphamide or mycophenolate mofetil as induction treatment for lupus nephritis, but the most exciting areas of research in lupus nephritis include the evolving comprehension of how factors specific to each patient and their expression of disease may guide treatment. For example, the 2012 ACR guidelines point out that mycophenolate mofetil is preferred over cyclophosphamide as induction therapy for class III and IV lupus nephritis in African American and Hispanic patients.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A randomized trial of multi-target induction therapy with tacrolimus plus mycophenolate mofetil vs. cyclophosphamide alone in patients with lupus nephritis across 26 renal centers in China showed multi-target treatment was superior in this population, and this has had important implications for use of calcineurin inhibitors in Asian patients with lupus nephritis.4

Partnership for Drug Targets
On a molecular level, researchers since 2003 have been investigating the prominent expression of interferon (IFN) regulated genes—an IFN signature—in the blood and tissues of patients with SLE, prompting such questions as: What is the cause of the IFN signature? Which cells produce IFN and does this change over different phases of the disease? Should treatment focus on blocking the IFN system in SLE and, if so, which is the most suitable target?5

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: ACR State-of-the-Art Clinical Symposium, Lupus nephritis, systemic lupus erythematosus (SLE)Issue: July 2020

You Might Also Like:
  • Treatment of Lupus Nephritis Continues to See Progress
  • Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances
  • 2015 ACR/ARHP Annual Meeting: Latest Clinical Literature Offers New Strategies in Lupus Nephritis
  • 2014 ACR/ARHP Annual Meeting: Lupus Nephritis

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)